Sun Pharma, the leading pharmaceutical company in India, has announced its plan to acquire Checkpoint Therapeutics for a significant sum of $355 million. This strategic move is aimed at bolstering Sun Pharma’s specialty portfolio, particularly with the addition of UNLOXCYT, an FDA-approved medication for advanced skin cancer. The acquisition will not only strengthen Sun Pharma’s position in the oncology treatment segment but also expand its footprint in the global market. This deal signifies Sun Pharma’s commitment to diversifying its product offerings and catering to the growing demand for innovative treatments in the healthcare industry. With this acquisition, Sun Pharma is poised to further solidify its presence as a key player in the pharmaceutical sector, both in India and internationally.